Quick Takeaways
- This page summarizes William B. Hayes's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
- 3 reported transactions and 3 derivative rows are listed below.
- Filing timestamp: 11 Apr 2025, 16:15.
William B. Hayes - 10 Apr 2025 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)
- Role
- Director
- Signature
- /s/ William Hayes
- Issuer symbol
- INDP
- Transactions as of
- 10 Apr 2025
- Net transactions value
- -$500
- Form type
- 4
- Filing time
- 11 Apr 2025, 16:15:16 UTC
- Previous filing
- 18 Mar 2025
- Next filing
- 29 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"William B. Hayes filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 11 Apr 2025."
What Changed
- Previous filing in this sequence was filed on 18 Mar 2025.
- Current net transaction value: -$500.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INDP | Stock Option (right to buy) | Disposed to Issuer | $250 | -500 | -100% | $0.5000 | 0 | 10 Apr 2025 | Common Stock | 500 | $24.60 | Direct | F1 |
| transaction | INDP | Stock Option (right to buy) | Disposed to Issuer | $125 | -250 | -100% | $0.5000 | 0 | 10 Apr 2025 | Common Stock | 250 | $388.64 | Direct | F1 |
| transaction | INDP | Stock Option (right to buy) | Disposed to Issuer | $125 | -250 | -100% | $0.5000 | 0 | 10 Apr 2025 | Common Stock | 250 | $355.20 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. |